Proficio Capital Partners LLC Makes New Investment in DaVita Inc. (NYSE:DVA)

Proficio Capital Partners LLC bought a new position in shares of DaVita Inc. (NYSE:DVA) during the fourth quarter, HoldingsChannel.com reports. The firm bought 37,687 shares of the company’s stock, valued at approximately $5,636,000.

Other institutional investors also recently made changes to their positions in the company. Atria Investments Inc grew its holdings in DaVita by 12.3% in the 3rd quarter. Atria Investments Inc now owns 2,897 shares of the company’s stock valued at $475,000 after buying an additional 317 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in DaVita by 1.8% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 126,071 shares of the company’s stock valued at $20,667,000 after buying an additional 2,186 shares during the period. Huntington National Bank grew its holdings in DaVita by 39.1% in the 3rd quarter. Huntington National Bank now owns 768 shares of the company’s stock valued at $126,000 after buying an additional 216 shares during the period. Empowered Funds LLC grew its holdings in shares of DaVita by 25.6% during the 3rd quarter. Empowered Funds LLC now owns 5,824 shares of the company’s stock worth $955,000 after purchasing an additional 1,187 shares during the period. Finally, Thrivent Financial for Lutherans grew its holdings in shares of DaVita by 49.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 8,131 shares of the company’s stock worth $1,333,000 after purchasing an additional 2,688 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DVA has been the subject of a number of research reports. Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research report on Friday, February 21st. Finally, Barclays boosted their price target on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $166.33.

DaVita Price Performance

Shares of DVA opened at $143.56 on Monday. The company has a market cap of $11.48 billion, a P/E ratio of 13.37, a PEG ratio of 1.07 and a beta of 0.99. The stock has a fifty day moving average price of $158.92 and a 200 day moving average price of $157.65. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.